Further studies will be performed to evaluate the nuclear eIF2α activity and to improve the emerging knowledge relating translational reprogramming to the invasive phase of melanoma, in order to contribute to the development of new target treatments for metastatic melanoma. The gene discussed is EIF2A; the disease is melanoma.